Drugs / CX-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07308834 | Feb 2026 → Oct 2028 expected | osteoarthritis, knee | CarthroniX, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07308834 ↗ |
| Modality | Small molecule | “CX-011 is a hydrophobic small molecule for intra-articular (IA) administration that is being developed for the treatment of subjects with osteoarthritis of the knee.” NCT07308834 ↗ |
| Route | Other | “CX-011 is a hydrophobic small molecule for intra-articular (IA) administration that is being developed for the treatment of subjects with osteoarthritis of the knee.” NCT07308834 ↗ |